Astonea Labs Ltd Stock Price Today (NSE: ASTONEALAB)
Fundamental Score
Astonea Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Astonea Labs Ltd share price today is ₹153.10, up +0.00% on NSE/BSE as of 30 March 2026. Astonea Labs Ltd (ASTONEALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹157.67 (Cr). The 52-week high for ASTONEALAB share price is ₹185.00 and the 52-week low is ₹118.00. At a P/E ratio of 33.98x, ASTONEALAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 44.66% and a debt-to-equity ratio of 0.73.
Astonea Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Astonea Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Astonea Labs Share Price: A Conservative Value Investor's Perspective
The pharmaceutical industry, known for its defensive characteristics and high regulatory hurdles, often presents compelling opportunities for value investors. This analysis examines the financials of Astonea Labs share price (₹157.0) through a conservative lens, focusing on capital preservation and intrinsic value. The company currently trades at a PE ratio of 33.98, which prompts a deeper investigation into its profitability and growth prospects relative to its peers.
A cornerstone of our fundamental analysis is Return on Capital Employed (ROCE). Astonea Labs boasts a ROCE of 19.74%. From a value perspective, this number is quite exciting. A high ROCE indicates efficient capital allocation and the potential for the company to generate strong returns on invested capital. This contributes to the creation of an economic moat, potentially shielding it from competitive pressures. The ability to consistently generate high returns on capital is crucial for long-term value creation. A sustainable ROCE over the long run is what we would look for.
When compared with sector peers such as
Mankind Pharma Ltd, it's vital to assess aspects like management quality and operational efficiency. While quantitative metrics provide a snapshot of current performance, a qualitative assessment of management's track record in capital allocation and strategic decision-making is paramount. For instance, if Mankind Pharma Ltd. is viewed to be managed more efficiently and with greater integrity by market participants, then Astonea's stock price may be considered as less enticing.The higher PE ratio does imply that there are assumptions of revenue growth, and/or margin expansion factored into the Astonea Labs share price. In order to take a confident position on Astonea, a full 80-parameter fundamental audit was performed by Sweta Mishra. Please note that this analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Astonea Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTONEALAB across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Return on Equity (44.66%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.74%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (40.24%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (72.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Profit Decline Concern (-33.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 2.86%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Astonea Labs Ltd Financial Statements
Comprehensive financial data for Astonea Labs Ltd including income statement, balance sheet and cash flow
About ASTONEALAB (Astonea Labs Ltd)
Astonea Labs Ltd is a dynamic pharmaceutical company dedicated to improving global health and well-being through the development, manufacturing, and distribution of high-quality ph...armaceutical and cosmetic products. Driven by innovation and a commitment to excellence, ASTONEALAB meticulously formulates and produces a diverse portfolio of medicines and personal care solutions designed to meet the evolving needs of patients and consumers worldwide. Our unwavering focus on research and development ensures that we remain at the forefront of scientific advancements, constantly exploring new therapeutic possibilities and pushing the boundaries of product efficacy and safety. ASTONEALAB strives to be a trusted partner for healthcare professionals and individuals seeking reliable and effective solutions for a healthier and more vibrant life. ASTONEALAB's product range encompasses a broad spectrum of therapeutic areas, addressing various health concerns and enhancing the quality of life. We offer a comprehensive selection of pharmaceutical products, including essential generic medications, over-the-counter remedies, specialized therapies targeting specific conditions, and innovative nutraceuticals designed to support overall wellness. Furthermore, ASTONEALAB's commitment to beauty and personal care is reflected in our extensive line of cosmetic products, which includes advanced skincare formulas, revitalizing haircare solutions, and age-defying treatments. Our dedication to quality extends across all product categories, ensuring that every item bearing the ASTONEALAB name meets the highest standards of purity, potency, and efficacy. ASTONEALAB operates with a global vision, extending its reach to serve diverse markets and communities around the world. We are committed to fostering strong partnerships with healthcare providers, distributors, and other stakeholders to ensure that our products are readily accessible to those who need them most. Through strategic collaborations and a robust distribution network, ASTONEALAB is expanding its presence in both established and emerging markets, bringing innovative healthcare solutions to a wider audience. We remain steadfast in our mission to make a positive impact on the health and well-being of individuals and communities worldwide, guided by our core values of integrity, innovation, and unwavering commitment to quality.
Company Details
Key Leadership
ASTONEALAB Share Price: Frequently Asked Questions
What is the current share price of Astonea Labs Ltd (ASTONEALAB)?
As of 30 Mar 2026, 12:04 pm IST, Astonea Labs Ltd share price is ₹153.10. The ASTONEALAB stock has a market capitalisation of ₹157.67 (Cr) on NSE/BSE.
Is ASTONEALAB share price Overvalued or Undervalued?
ASTONEALAB share price is currently trading at a P/E ratio of 33.98x, compared to the industry average of 31.77x. Based on this relative valuation, the Astonea Labs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ASTONEALAB share price?
The 52-week high of ASTONEALAB share price is ₹185.00 and the 52-week low is ₹118.00. These values are updated daily from NSE/BSE price data.
What factors affect the Astonea Labs Ltd share price?
Key factors influencing ASTONEALAB share price include quarterly earnings growth (Sales Growth: 40.24%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Astonea Labs Ltd a good stock for long-term investment?
Astonea Labs Ltd shows a 5-year Profit Growth of N/A% and an ROE of 44.66%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.73 before investing in ASTONEALAB shares.
How does Astonea Labs Ltd compare with its industry peers?
Astonea Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare ASTONEALAB share price P/E of 33.98x and ROE of 44.66% against the industry averages to determine competitive standing.
What is the P/E ratio of ASTONEALAB and what does it mean?
ASTONEALAB share price has a P/E ratio of 33.98x compared to the industry average of 31.77x. Investors pay ₹34 for every ₹1 of annual earnings.
How is ASTONEALAB performing according to Bull Run's analysis?
ASTONEALAB has a Bull Run fundamental score of 31.6/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ASTONEALAB belong to?
ASTONEALAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Astonea Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for ASTONEALAB?
ASTONEALAB has an ROE of 44.66%, which indicates excellent management efficiency. ROE measures how efficiently Astonea Labs Ltd generates profits from shareholders capital.
How is ASTONEALAB debt-to-equity ratio and what does it indicate?
ASTONEALAB has a debt-to-equity ratio of 0.73, which indicates moderate leverage that should be monitored.
What is ASTONEALAB dividend yield and is it a good dividend stock?
ASTONEALAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Astonea Labs Ltd shares.
How has ASTONEALAB share price grown over the past 5 years?
ASTONEALAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ASTONEALAB and why does it matter?
Promoters hold 72.30% of ASTONEALAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Astonea Labs Ltd.
What is ASTONEALAB market capitalisation category?
ASTONEALAB has a market capitalisation of ₹158 crores, placing it in the Small-cap category.
How volatile is ASTONEALAB stock?
ASTONEALAB has a beta of N/A. A beta > 1 suggests the Astonea Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ASTONEALAB operating profit margin trend?
ASTONEALAB has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ASTONEALAB quarterly performance?
Recent quarterly performance shows Astonea Labs Ltd YoY Sales Growth of 40.24% and YoY Profit Growth of -33.33%.
What is the institutional holding pattern in ASTONEALAB?
ASTONEALAB has FII holding of 2.51% and DII holding of 0.35%. Significant institutional holding often suggests professional confidence in the Astonea Labs Ltd stock.